SFAM
ASND icon

Springhill Fund Asset Management’s Ascendis Pharma A/S ASND Stock Holding History

Springhill Fund Asset Management’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,173
Closed -$339K – 3
2025
Q1 		$339K Buy
+2,173
New +$310K 1.62% 15

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Springhill Fund Asset Management's ASND Position: Q2 2025 in Review

Springhill Fund Asset Management sold out of Ascendis Pharma A/S (ASND) in Q2 2025, closing a stake of 2,173 shares — an estimated $339K sold.

Springhill Fund Asset Management first reported a position in ASND in Q1 2025 and held it in 1 quarter. The position peaked at $339K in Q1 2025. 247 funds tracked by Wall St. Rank hold ASND as of Q2 2025.

  • Springhill Fund Asset Management reported no remaining Ascendis Pharma A/S position as of Q2 2025 after selling out during the quarter.
  • Springhill Fund Asset Management sold 2,173 Ascendis Pharma A/S shares in Q2 2025, an estimated $339K.
  • Springhill Fund Asset Management first reported a position in Ascendis Pharma A/S in Q1 2025 and held it in 1 quarter.
  • Springhill Fund Asset Management's Ascendis Pharma A/S position peaked at $339K in Q1 2025.
  • 247 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2025.

Based on Springhill Fund Asset Management's 13F filing for Q2 2025.